Effects of tanshinone IIA on the regulation of renal proximal tubular fibrosis

丹参酮ⅡA对肾近端小管纤维化的调控作用

阅读:12
作者:Luoyuan Cao, Baoying Huang, Xianguo Fu, Jing Yang, Yinghua Lin, Feng Lin

Abstract

The development of diabetes mellitus, along with its complications, is a chronic inflammatory response process. Chronic kidney diseases are characterized by renal fibrosis, and fibrosis is an important pathway for end‑stage renal failure. According to previous studies, high glucose (HG) has been demonstrated to be the most important fibrogenesis‑inducing agent. Tanshinone IIA is one of the main components isolated from Danshen (Salvia miltiorrhiza). Although tanshinone IIA has been widely used for the treatment of cardiovascular diseases, the possible role of tanshinone IIA in fibrosis regulation remains to be elucidated and requires investigation. In the present study, renal proximal tubular epithelial cells (HK‑2) were treated with HG (30 mM glucose) to determine whether tanshinone IIA (1, 10 and 50 µM) had an effect on the regulation of renal cellular fibrosis. The results demonstrated that 50 µM tanshinone IIA may exert optimal inhibitory effects on HG‑induced Snail, fibronectin, vimentin and α‑smooth muscle actin (α‑SMA) expression in HK‑2 cells after 48 h. Tanshinone IIA also reversed HG‑induced morphological alterations in HK‑2 cells and inhibited an HG‑induced increase in fibronectin and α‑SMA mRNA and protein and an HG‑induced decrease in E‑cadherin. Furthermore, tanshinone IIA suppressed an HG‑induced increase in Snail, which is a transcription factor that can suppress E‑cadherin expression. E‑cadherin is a major component of adherens junctions and a characteristic of epithelial integrity. Tanshinone IIA reversed HG‑induced increase in α‑SMA and decrease in E‑cadherin. These data suggest that tanshinone IIA has the potential to inhibit HG‑induced renal tubular epithelial cell fibrosis possibly through the epithelial‑myofibroblast transdifferentiation pathway. Therefore, tanshinone IIA may be considered a renoprotective agent for the treatment of renal fibrosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。